How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...
RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.20 since the market last closed. This is a 4.96% ...
The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Ricursive Intelligence founders Anna Goldie and Azalia Mirhoseini believe more efficient AI chip design could help solve the compute crisis. The founders took the stage at TechCrunch Disrupt on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results